Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients | Zendy

Jutta Beier | Zendy; Vera E. van der Noord | Zendy; Deans | Zendy; Peter Brooks | Zendy; Maden | Zendy

Open Access

Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients

Author(s) -

Jutta Beier,

Vera E. van der Noord,

Deans,

Peter Brooks,

Maden

Publication year - 2012

Publication title -

international journal of copd

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 67

eISSN - 1178-2005

pISSN - 1176-9106

DOI - 10.2147/copd.s26100

Subject(s) - salmeterol , medicine , placebo , copd , bronchodilator , crossover study , anesthesia , tiotropium bromide , clinical endpoint , randomized controlled trial , asthma , lung , lung function , alternative medicine , pathology

GSK233705 is an inhaled, long-acting muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD). This study was performed to see if the addition of GSK233705 to salmeterol would provide greater bronchodilation than salmeterol or tiotropium alone in COPD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research